Analysis reveals 9.4% prevalence of dMMR in solid tumors, highlighting the importance of biomarker testing for immune checkpoint inhibitors in treatment decisions.
Key Points
Prevalence of dMMR was found to be 9.4% across five solid tumor types in Chinese patients.
Endometrial tumors had the highest dMMR prevalence at 29.9%, while cervical tumors had the lowest at 2.7%.
Tissue samples were analyzed using immunohistochemistry with the Ventana MMR RxDx panel to determine dMMR status.
These findings underline the significance of dMMR testing for optimizing biomarker testing and treatment options.